12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

UMN-0501: Phase II data

Astellas and UMN Pharma said that "immunogenicity and favorable tolerability" have been observed in 180 healthy volunteers in a double-blind, Japanese Phase II trial evaluating 3 doses...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >